argenex SE (NASDAQ:ARGX – Get Free Report) shares were up 4.8% on Friday . The stock traded as high as $879.09 and last traded at $883.0790. Approximately 263,762 shares were traded during mid-day trading, a decline of 24% from the average daily volume of 348,502 shares. The stock had previously closed at $842.27.
Analyst Ratings Changes
Several analysts have commented on ARGX shares. Guggenheim increased their price target on shares of argenex from $1,120.00 to $1,135.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. Royal Bank Of Canada decreased their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research report on Friday, February 27th. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Finally, Wedbush reissued an “outperform” rating and set a $1,000.00 price target on shares of argenex in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, argenex has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.
Read Our Latest Stock Analysis on ARGX
argenex Stock Up 5.0%
argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. The firm had revenue of $1.31 billion during the quarter. argenex had a net margin of 31.31% and a return on equity of 33.28%. On average, sell-side analysts forecast that argenex SE will post 26.19 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of ARGX. AQR Capital Management LLC increased its stake in argenex by 32.1% during the 1st quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares in the last quarter. NewEdge Advisors LLC increased its stake in argenex by 5,962.5% during the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock valued at $862,000 after purchasing an additional 1,431 shares in the last quarter. Focus Partners Wealth increased its stake in argenex by 22.3% during the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock valued at $237,000 after purchasing an additional 73 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in argenex by 550.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after purchasing an additional 99 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its stake in argenex by 60.2% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 133 shares of the company’s stock valued at $73,000 after purchasing an additional 50 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Featured Articles
- Five stocks we like better than argenex
- AI Server Earnings: Wall Street Sees One Clear Standout
- Navitas: NVIDIA’s AI Power Broker?
- A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below
- NVIDIA’s New Power Play: Why Fluence Is Surging
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
